Top Internal Health Stories for August 26th.

Hello, and welcome to Inner Healthcare. I am Mohana Ravinder Nath, and I cover the future of digital health and healthcare. In today’s health news:

If you are new to this newsletter, sign up here. Send suggestions, grips, comments and predictions for the future of healthcare to mravindranath@insider.com or tweet. Round ind.. To the news …


Johnson & Johnson vaccine

Nurse Elizabeth Johnson administered the Covid 19 vaccine to Melissa Mendes in Reading, Pennsylvania.

Reading Entity / Media News Group / Eagle / Getty Images.


J&J says its single dose of COVID-19 vaccine booster shot raises antibody levels and can be given eight months after the first dose

  • Johnson & Johnson’s only dose The second dose of the COVID-19 vaccine boosted antibodies in a small study.
  • After the second dose, the antibody level was nine times higher than the original.
  • The company plans to meet with US health officials to discuss the possibility of administering the booster eight months after the first dose.

Read more >>


Covid vaccine card

COVID-19 vaccine card at the Brixham Nursing and Rehabilitation Center in Burns Township, Pennsylvania on January 19, 2021.

Ben Entity / Media News Group / Reading Eagle / Getty Images.


Report: The Biden administration will likely recommend Covid 19 booster shots six months later instead of eight.

  • The Biden administration will approve COVID-19 booster shots for potentially immunized adults, according to the Wall Street Journal.
  • The administration had earlier said it would call for a booster for eight months.
  • The move is based on data from vaccine makers on a six-month booster shot schedule.

Get the news >>.


Clinical Trial Lab Research Drug Medicine.

Clinical Trial Lab Research Drug Medicine.

Getty


There is a problem with diversity in clinical trials, but tech may not be the answer.

  • Startups are bringing together millions of people using state-of-the-art marketing and messaging technology to reach more ethnically and socio-economically diverse patients.
  • Clinical trials generally underestimate ethnic minorities, although the development of the COVID-19 vaccine has highlighted this problem for large pharmaceutical companies.
  • Equity experts say the technology may not address the real issues that keep minorities out of clinical trials, including a lack of access to healthcare.

Read the full story >>


More stories we are reading:

  • The full name of the Pfizer vaccine is a mesh-up of the full name – comorbidity – “covid 19”, “mRNA”, and much more (internal).
  • Mental health-focused tech companies merge headspace and ginger (state)
  • A new study at the JAMA Network Open finds abortion safe and effective with telehealth-facilitated drugs (MobyHealthNews)
  • Steven Blum explores how social media transforms “digital afterlife” and sadness (wired)

OMohana

Leave a Reply

Your email address will not be published.